Management of Behcet's syndrome

Ozguler Y., Hatemi G.

CURRENT OPINION IN RHEUMATOLOGY, cilt.28, sa.1, ss.45-50, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 28 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1097/bor.0000000000000231
  • Dergi Adı: CURRENT OPINION IN RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.45-50
  • İstanbul Üniversitesi Adresli: Evet

Özet

Purpose of reviewCurrent trends in the management of Behcet's syndrome will be reviewed in this article.Recent findingsBiologic agents have gained increasing importance over the years in the management of Behcet's syndrome. Long-term results of observational studies have shown that anti-tumor necrosis factor agents may be effective in Behcet's syndrome patients with refractory eye involvement. Case series reporting about use of anti-tumor necrosis factor agents in vascular and gastrointestinal involvement have also shown good results. Caution is required for infectious complications with these agents. Apremilast is an immunomodulatory agent that works through phosphodiesterase 4 inhibition. A randomized controlled trial has shown that it is effective for the management of oral and genital ulcers and is generally well tolerated.SummaryThe outcome of Behcet's syndrome with major organ involvement has improved with more effective management strategies, especially with the use of biologic agents in severe cases. Controlled trials are needed to guide physicians in making treatment decisions.